Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · IEX Real-Time Price · USD
20.78
-0.37 (-1.75%)
At close: Jul 19, 2024, 4:00 PM
20.31
-0.47 (-2.26%)
Pre-market: Jul 22, 2024, 8:37 AM EDT
Nurix Therapeutics Employees
Nurix Therapeutics had 284 employees as of November 30, 2023. The number of employees decreased by 13 or -4.38% compared to the previous year.
Employees
284
Change (1Y)
-13
Growth (1Y)
-4.38%
Revenue / Employee
$219,377
Profits / Employee
-$580,993
Market Cap
1.34B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Nov 30, 2023 | 284 | -13 | -4.38% |
Nov 30, 2022 | 297 | 55 | 22.73% |
Nov 30, 2021 | 242 | 107 | 79.26% |
Nov 30, 2020 | 135 | 42 | 45.16% |
Nov 30, 2019 | 93 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Phreesia | 1,438 |
ANI Pharmaceuticals | 642 |
Gyre Therapeutics | 593 |
Vir Biotechnology | 587 |
Arcus Biosciences | 577 |
Dynavax Technologies | 408 |
Day One Biopharmaceuticals | 155 |
Disc Medicine | 74 |
NRIX News
- 10 days ago - Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 5 weeks ago - Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024) - GlobeNewsWire
- 7 weeks ago - Nurix Therapeutics Appoints Paula G. O'Connor, M.D. - GlobeNewsWire
- 2 months ago - Nurix Therapeutics Announces Board Chair Transition - GlobeNewsWire
- 2 months ago - Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024) - GlobeNewsWire
- 2 months ago - Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 3 months ago - Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering - GlobeNewsWire